SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase

被引：8
|
作者：
Huber, Sandra [1 ]
Haferlach, Torsten [1 ]
Meggendorfer, Manja [1 ]
Hutter, Stephan [1 ]
Hoermann, Gregor [1 ]
Baer, Constance [1 ]
Kern, Wolfgang [1 ]
Haferlach, Claudia [1 ]
机构：
[1] MLL Munich Leukemia Lab, Max Lebsche Pl 31, D-81377 Munich, Germany
来源：
LEUKEMIA | 2022年 / 36卷 / 12期
关键词：
CLASSIFICATION; LANDSCAPE;
D O I：
10.1038/s41375-022-01734-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2927 / 2930
页数：4
相关论文
共 50 条
  • [31] CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1
    Marco Ayala, J.
    Senent Peris, M. L.
    Vicente, A., I
    Saumell, S.
    Such, E.
    Blanco, A.
    Diaz, A.
    Luna, I
    De la Puerta, R.
    Sanz, G.
    HAEMATOLOGICA, 2019, 104 : 290 - 290
  • [32] Molecular Evaluation of SF3B1 Mutations in Cytopenic Patients
    Goyal, B.
    Duncavage, E. J.
    MODERN PATHOLOGY, 2013, 26 : 329A - 330A
  • [33] A Murine Model Harboring Cooperating DNMT3A and SF3B1 Mutations Phenocopies SF3B1 Driven Myelodysplastic Syndrome
    Wallace, Lashanale
    Leal-Cervantes, Ana
    Metidji, Amina
    Myers, Jacquelyn
    Rolle, Chandra
    Tillman, Heather
    Obeng, Esther A.
    BLOOD, 2022, 140 : 5862 - 5863
  • [34] Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations
    Moura, Pedro Luis
    Hofman, Isabel Juliana F.
    Nannya, Yasuhito
    Aliouat, Affaf
    Mortera-Blanco, Teresa
    Yoshizato, Tetsuichi
    Saiki, Ryunosuke
    Nakagawa, Masahiro Marshall
    Bjorklund, Ann-Charlotte
    Walldin, Gunilla
    Barbosa, Indira
    Jansson, Monika
    Grasso, Francesca
    Creignou, Maria
    Elvarsdottir, Edda Maria
    Woll, Petter S.
    Jacobsen, Sten Eirik Waelgaard
    Ogawa, Seishi
    Hellstrom-Lindberg, Eva
    BLOOD, 2022, 140 : 6898 - 6899
  • [35] Distinct methylation signature in MDS patients with SF3B1 mutations confers a novel mechanism of disease pathogenesis
    Visconte, V.
    Zhang, L.
    Mahfouz, R.
    Tabarroki, A.
    Rogers, H. J.
    Hasrouni, E.
    Hamilton, B.
    Jankowska, A.
    Barnard, J.
    Traina, F.
    Duong, H.
    Saunthararajah, Y.
    Lichtin, A.
    Horwitz, L.
    Sekeres, M. A.
    Tiu, R. V.
    LEUKEMIA RESEARCH, 2013, 37 : S27 - S27
  • [36] Molecular Evaluation of SF3B1 Mutations in Cytopenic Patients
    Goyal, B.
    Duncavage, E. J.
    LABORATORY INVESTIGATION, 2013, 93 : 329A - 330A
  • [37] SF3B1 and DNMT3A Mutations Might Play a Role in Poor Prognosis and AML Progression in Patients With Isolated del(5q) MDS
    Rey-Bua, Beatriz
    Toribio-Castello, Sofi A.
    Bonome-Gonzalez, Merelyn
    Villaverde-Ramiro, Angela
    Gonzalez, Teresa
    Del Rey, Monica
    Hernandez-Rivas, Jesus Maria
    Yeguas, Ana
    Avendano, Alejandro
    Gomez-Ubeda, Sandra Patricia
    Santos, Marta Fonseca
    Puertas, Borja
    Alonso, Elena Alejo
    Diez-Campelo, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S316 - S316
  • [38] Co-Existing ASXL1 and SF3B1 Mutations Carried Worse Outcome Than ASXL1 or SF3B1 Mutations Alone
    Song, Jinming
    Moscinski, Lynn C.
    Yang, Ethan
    Hussaini, Mohammad
    Zhang, Hailing
    BLOOD, 2022, 140 : 4026 - 4027
  • [39] Low frequencies of SF3B1 mutations indicate SF3B1 inhibitor as a novel moleculartargeted drug for colorectal cancer.
    Yamano, Tomoki
    Nakajima, Hidenori
    Tsuda, Satoshi
    Kubo, Shuji
    Hamanaka, Mie
    Kobayashi, Masayoshi
    Yamagishi, Daisuke
    Kuno, Takashi
    Tsukamoto, Kiyoshi
    Tamamoto, Astuko
    Noda, Masafumi
    Matsubara, Nagahide
    Hoon, Dave S. B.
    Tomita, Naohiro
    CANCER RESEARCH, 2013, 73 (08)
  • [40] Clonal shifts in MDS - from SF3B1 to EZH2
    Ribeiro, Andre Barbosa
    Coucelo, Margarida
    Tenreiro, Rita
    Simoes, Ana Teresa
    Marques, Gilberto
    Ribeiro, Leticia
    Cortesao, Emilia
    Sarmento-Ribeiro, Ana Bela
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2994 - 2997
12345